Article Roles of Supersaturation and Liquid–Liquid Phase Separation for Enhanced Oral Absorption of Poorly Soluble Drugs from Amorphous Solid Dispersions

Kohsaku Kawakami SAMURAI ORCID

Collection

Citation
Kohsaku Kawakami. Roles of Supersaturation and Liquid–Liquid Phase Separation for Enhanced Oral Absorption of Poorly Soluble Drugs from Amorphous Solid Dispersions. Pharmaceutics. 2025, 17 (2), 262. https://doi.org/10.3390/pharmaceutics17020262

Description:

(abstract)

Amorphous solid dispersion (ASD) is one of the most important enabling formulation technologies for the development of poorly soluble drugs. Because of its thermodynamically unstable nature in both solid and wet states, the evaluation and optimization of the formulation performance involves some difficulties. The dissolution process is sensitively influenced by various factors, including the applied dose, medium composition, and pH. Supersaturated solutions can cause liquid–liquid phase separation (LLPS) and/or crystallization, which complicates the comprehension of the dissolution process. However, LLPS should be evaluated carefully because it is closely related to oral absorption. As LLPS concentration is analogous to amorphous solubility, it can be a key factor in predicting oral absorption from ASDs, if absorption is limited by solubility. Moreover, LLPS droplets are expected to increase transmembrane flux by increasing the drug concentration near the epithelial cell membrane. In this review, recently updated knowledge on the dissolution, membrane permeation, and oral absorption behaviors of ASDs is discussed with an emphasis on LLPS behavior.

Rights:

Keyword: Amorphous solid dispersion, Crystallizaion, Supersaturation, Liquid–liquid phase separation, Membrane permeability, Oral absorption

Date published: 2025-02-16

Publisher: MDPI AG

Journal:

  • Pharmaceutics (ISSN: 19994923) vol. 17 issue. 2 262

Funding:

Manuscript type: Publisher's version (Version of record)

MDR DOI:

First published URL: https://doi.org/10.3390/pharmaceutics17020262

Related item:

Other identifier(s):

Contact agent:

Updated at: 2025-04-30 12:30:20 +0900

Published on MDR: 2025-04-30 12:23:10 +0900

Filename Size
Filename 2025pharmaceutics.pdf (Thumbnail)
application/pdf
Size 3.69 MB Detail